Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Español de Tratamiento en Hematología Pediatric-Based Protocol ALL-96

Abstract

The response to the pediatric ALL-96 protocol was identical in adolescents and young adults despite a slight increase in hematologic toxicity observed in adults. This justifies the age-unrestricted use of pediatric regimens to treat patients with SR ALL.

Acute Lymphoblastic Leukemia in Adolescents and Young Adults

“…The Spanish PETHEMA group compared the results of the pediatric protocol ALL96 in adolescents (15-18yr, n=35) and young adults (18-30 yr, n=46) with standard-risk (SR) ALL (Ribera et al 2008). Both groups were comparable for the main clinical and biologic characteristics of ALL.…”

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

“…Since 1989, the PETHEMA (Programa Español de Tratamiento en Hematologia) trials have used a common backbone of treatment for adult patients with newly diagnosed ALL, consisting of 4 weeks of induction therapy, early consolidation with short courses of combined active drugs and delayed consolidation, including further courses of combined cytotoxic drugs, followed by 2 years of maintenance treatment or, alternatively, an autologous or allogeneic SCT in some patients with high-risk ALL. [13][14][15][16] Data from a very extended follow-up of this large cohort of prospectively enrolled patients after a common approach to initial therapy are currently available, thereby providing optimal information for identifying prognostic factors for the achievement of a second remission and subsequent survival in patients with relapsed ALL and for defining subsets of patients likely to benefit from rescue treatment. We analyzed the outcome of 263 adult patients who relapsed following treatment in the PETHEMA ALL89, 13 ALL93HR, 14 ALL96SR, 16 and ALL03HR 17 trials.…”

“…[13][14][15][16] Data from a very extended follow-up of this large cohort of prospectively enrolled patients after a common approach to initial therapy are currently available, thereby providing optimal information for identifying prognostic factors for the achievement of a second remission and subsequent survival in patients with relapsed ALL and for defining subsets of patients likely to benefit from rescue treatment. We analyzed the outcome of 263 adult patients who relapsed following treatment in the PETHEMA ALL89, 13 ALL93HR, 14 ALL96SR, 16 and ALL03HR 17 trials.…”

Leucemia linfoblástica aguda estirpe B Philadelphia negativa en adolescentes y adultos jóvenes: Resultados del Protocolo Terapéutico LLA 15-30, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile

“…La intensificación del tratamiento mantuvo una baja tasa de mortalidad por toxicidad, de 6%, similar a lo observado en la literatura [15][16] . A su vez, la reciente centralización del tratamiento de las leucemias agudas en hospitales calificados y su incorporación al programa de Garantías Explícitas en Salud (GES) en julio de 2007, así como la implementación de protocolos basados en evidencia, han permitido mejorar los resultados en patologías de alta complejidad como la LLA.…”

“…1 encargado de Protocolo lla [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30]. 2 Hematóloga unidad de Hematología intensiva, Hospital del salvador.…”